Trial results published in the Lancet suggest the new appetite suppressing pill by pharmaceutical giant Eli Lilly worked best for patients with Type 2 diabetes, with two positive outcomes ...
Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes patients, giving a more ...
The newly-approved device requires only that patients swallow it in their doctor's office to achieve weight loss, according to Allurion Technologies.
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be ...
Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.
Ozempic and similar weight-loss medications are hailed as miracle drugs. But there are plenty of unknows about long-term use.
If I've ever been able to boast about anything, it's that I've never been fat. Admittedly, I've also never had a particularly ...
Two sleep doctors weigh in on the top ingredients to look for when shopping, and based on their recommendations and the ...
The new review brings together the strongest evidence to date on collagen supplementation, say experts.
A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 ...
Retatrutide helped trial participants lose up to 28.7% of their body weight, but experts warn about excessive weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results